Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AVEO Pharmaceuticals

AVEO Pharmaceuticals?uq=w9if130k
2001 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
AVEO STOCK SYMBOL
$2.26 SHARE PRICE (As of Thursday Closing)
Description

Operator of a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma.

Formerly Known As
GenPath Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • One Broadway, 14th Floor
  • Cambridge, MA 02142
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore AVEO Pharmaceuticals’s full profile, request a free trial.

AVEO Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.95 - $3.99 $259M $2.18 -$0.20 2.43M 119M

AVEO Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 269,281 315,069 31,621 48,645
Revenue 6,155 7,579 2,515 19,024
EBITDA (25,497) (62,551) (24,807) (3,148)
Net Income (27,882) (65,025) (26,887) (15,001)
Total Assets 20,006 50,198 27,285 40,542
Total Debt 18,730 18,477 14,003 9,471
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AVEO Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore AVEO Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

AVEO Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore AVEO Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

AVEO Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore AVEO Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

AVEO Pharmaceuticals Executive Team (12)

Name Title Board
Seat
Contact
Info
Michael Bailey Chief Executive Officer, Director & President
Matthew Dallas Chief Financial Officer
Michael Needle MD Chief Medical Officer

9 Former Executives

You’re viewing 3 of 12 executives. Get the full list »

AVEO Pharmaceuticals Board Members (13)

Name Representing Role Since Contact
Info
Henri Termeer Self Board Member 000 0000
Kenneth Bate Self Board Member 000 0000
Raju Kucherlapati Ph.D Self Board Member 000 0000
Robert Epstein MD Self Board Member 000 0000
Robert Young AVEO Pharmaceuticals Board Member 000 0000

7 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »